Skip NavigationSkip to Content

Germline pathogenic variants associated with triple-negative breast cancer in US Hispanic and Guatemalan women using hospital and community-based recruitment strategies

  1. Author:
    Godinez Paredes, Jesica M
    Rodriguez, Isabel
    Ren, Megan
    Orozco, Anali
    Ortiz, Jeremy
    Albanez, Anaseidy
    Jones, Catherine
    Nahleh, Zeina
    Barreda, Lilian
    Garland,Lisa
    Torres-Gonzalez, Edmundo
    Wu,Dongjing
    Luo,Wen
    Liu,Jia
    Argueta, Victor
    Orozco, Roberto
    Gharzouzi, Eduardo
    Dean, Michael [ORCID]
  2. Author Address

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Gaithersburg, MD, USA., Instituto Cancerologia, Guatemala City, Guatemala., Texas Tech University Health Sciences Center, Lubbock, TX, USA., Cleveland Clinic Florida, Weston, FL, USA., Hospital General San Juan de Dios, Guatemala City, Guatemala., Cancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, Frederick National Laboratory for Cancer Research, Gaithersburg, MD, USA., Integra Cancer Center, Guatemala City, Guatemala., Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Gaithersburg, MD, USA. deanm@mail.nih.gov., National Cancer Institute, 9615 Medical Center Drive, Rm 3130, Rockville, MD, 20850, USA. deanm@mail.nih.gov.,
    1. Year: 2024
    2. Date: Mar 23
    3. Epub Date: 2024 03 23
  1. Journal: Breast Cancer Research and Treatment
  2. Type of Article: Article
  1. Abstract:

    Recruit and sequence breast cancer subjects in Guatemalan and US Hispanic populations. Identify optimum strategies to recruit Latin American and Hispanic women into genetic studies of breast cancer. We used targeted gene sequencing to identify pathogenic variants in 19 familial breast cancer susceptibility genes in DNA from unselected Hispanic breast cancer cases in the US and Guatemala. Recruitment across the US was achieved through community-based strategies. In addition, we obtained patients receiving cancer treatment at major hospitals in Texas and Guatemala. We recruited 287 Hispanic US women, 38 (13%) from community-based and 249 (87%) from hospital-based strategies. In addition, we ascertained 801 Guatemalan women using hospital-based recruitment. In our experience, a hospital-based approach was more efficient than community-based recruitment. In this study, we sequenced 103 US and 137 Guatemalan women and found 11 and 10 pathogenic variants, respectively. The most frequently mutated genes were BRCA1, BRCA2, CHEK2, and ATM. In addition, an analysis of 287 US Hispanic patients with pathology reports showed a significantly higher percentage of triple-negative disease in patients with pathogenic variants (41% vs. 15%). Finally, an analysis of mammography usage in 801 Guatemalan patients found reduced screening in women with a lower socioeconomic status (p?< ?0.001). Guatemalan and US Hispanic women have rates of hereditary breast cancer pathogenic variants similar to other populations and are more likely to have early age at diagnosis, a family history, and a more aggressive disease. Patient recruitment was higher using hospital-based versus community enrollment. This data supports genetic testing in breast cancer patients to reduce breast cancer mortality in Hispanic women. © 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

    See More

External Sources

  1. DOI: 10.1007/s10549-024-07300-2
  2. PMID: 38520597
  3. PII : 10.1007/s10549-024-07300-2

Library Notes

  1. Fiscal Year: FY2023-2024
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel